Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Cash from Investing Activities (2021 - 2024)

Lyra Therapeutics (LYRA) has disclosed Cash from Investing Activities for 4 consecutive years, with $28.1 million as the latest value for Q4 2024.

  • On a quarterly basis, Cash from Investing Activities rose 1292.5% to $28.1 million in Q4 2024 year-over-year; TTM through Sep 2025 was $72.4 million, a 45.43% increase, with the full-year FY2024 number at $80.3 million, up 738.15% from a year prior.
  • Cash from Investing Activities was $28.1 million for Q4 2024 at Lyra Therapeutics, up from $8.1 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $36.2 million in Q2 2024 to a low of -$64.9 million in Q4 2022.
  • A 4-year average of -$41875.0 and a median of -$305000.0 in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: crashed 51551.72% in 2023, then surged 6548.48% in 2024.
  • Lyra Therapeutics' Cash from Investing Activities stood at -$1.1 million in 2021, then tumbled by 5889.84% to -$64.9 million in 2022, then soared by 96.36% to -$2.4 million in 2023, then surged by 1292.5% to $28.1 million in 2024.
  • Per Business Quant, the three most recent readings for LYRA's Cash from Investing Activities are $28.1 million (Q4 2024), $8.1 million (Q3 2024), and $36.2 million (Q2 2024).